TScan Therapeutics, Inc.
TCRX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $2,816 | $21,049 | $13,535 | $10,141 |
| % Growth | -86.6% | 55.5% | 33.5% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $2,816 | $21,049 | $13,535 | $10,141 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $107,350 | $88,153 | $59,819 | $44,954 |
| G&A Expenses | $29,559 | $25,492 | $20,352 | $13,828 |
| SG&A Expenses | $29,559 | $25,492 | $20,352 | $13,828 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $728 | $862 | $0 | $0 |
| Operating Expenses | $137,637 | $114,507 | $80,171 | $58,782 |
| Operating Income | -$134,821 | -$93,458 | -$66,636 | -$48,641 |
| % Margin | -4,787.7% | -444% | -492.3% | -479.6% |
| Other Income/Exp. Net | $7,322 | $4,240 | $415 | $16 |
| Pre-Tax Income | -$127,499 | -$89,218 | -$66,221 | -$48,625 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$127,499 | -$89,218 | -$66,221 | -$48,625 |
| % Margin | -4,527.7% | -423.9% | -489.3% | -479.5% |
| EPS | -1.14 | -1.36 | -2.74 | -2.03 |
| % Growth | 16.2% | 50.4% | -35% | – |
| EPS Diluted | -1.14 | -1.36 | -2.74 | -2.03 |
| Weighted Avg Shares Out | 111,990 | 65,600 | 24,048 | 23,908 |
| Weighted Avg Shares Out Dil | 111,990 | 65,600 | 24,048 | 23,908 |
| Supplemental Information | – | – | – | – |
| Interest Income | $12,065 | $7,999 | $1,591 | $16 |
| Interest Expense | $3,653 | $3,759 | $1,176 | $0 |
| Depreciation & Amortization | $4,108 | $5,361 | $5,137 | $3,328 |
| EBITDA | -$119,738 | -$80,098 | -$59,908 | -$45,297 |
| % Margin | -4,252.1% | -380.5% | -442.6% | -446.7% |